Insider Trading Alert - OPK, SLAB And APD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 24, 2014, 153 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $614.00 to $8,867,579,754,879.72.

Highlighted Stocks Traded by Insiders:

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 17,200 shares at $9.00 on Feb. 24, 2014. Following this transaction, the CEO & Chairman owned 139.3 million shares meaning that the stake was reduced by 0.01% with the 17,200-share transaction.

The shares most recently traded at $9.07, up $0.07, or 0.73% since the insider transaction. Historical insider transactions for Opko Health go as follows:

  • 4-Week # shares bought: 20,000
  • 4-Week # shares sold: 46,730
  • 12-Week # shares bought: 30,000
  • 12-Week # shares sold: 46,730
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 46,730

The average volume for Opko Health has been 4.0 million shares per day over the past 30 days. Opko Health has a market cap of $3.6 billion and is part of the health care sector and health services industry. Shares are up 5.92% year-to-date as of the close of trading on Monday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and weak operating cash flow. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Silicon Laboratories (SLAB) - FREE Research Report

Cash Harvey B who is Director at Silicon Laboratories sold 71,976 shares at $48.97 on Feb. 24, 2014. Following this transaction, the Director owned 0 shares meaning that the stake was reduced by 100% with the 71,976-share transaction.

The shares most recently traded at $50.73, up $1.76, or 3.48% since the insider transaction. Historical insider transactions for Silicon Laboratories go as follows:

  • 4-Week # shares sold: 18,516
  • 12-Week # shares sold: 25,016
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 42,085

The average volume for Silicon Laboratories has been 385,100 shares per day over the past 30 days. Silicon Laboratories has a market cap of $2.1 billion and is part of the technology sector and electronics industry. Shares are up 17.62% year-to-date as of the close of trading on Monday.

Silicon Laboratories Inc., a fabless semiconductor company, designs and develops analog-intensive, mixed-signal integrated circuits (ICs). The company has a P/E ratio of 43.9. Currently there are 6 analysts that rate Silicon Laboratories a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLAB - FREE

TheStreet Quant Ratings rates Silicon Laboratories as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Silicon Laboratories Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Air Products & Chemicals (APD) - FREE Research Report

Mattimore Patricia A who is Senior Vice President at Air Products & Chemicals sold 721 shares at $118.38 on Feb. 24, 2014. Following this transaction, the Senior Vice President owned 7,205 shares meaning that the stake was reduced by 9.1% with the 721-share transaction.

The shares most recently traded at $119.61, up $1.23, or 1.03% since the insider transaction. Historical insider transactions for Air Products & Chemicals go as follows:

  • 4-Week # shares bought: 3,645
  • 4-Week # shares sold: 2,000
  • 12-Week # shares bought: 3,645
  • 12-Week # shares sold: 2,000
  • 24-Week # shares bought: 18,645
  • 24-Week # shares sold: 3,380

The average volume for Air Products & Chemicals has been 1.1 million shares per day over the past 30 days. Air Products & Chemicals has a market cap of $25.0 billion and is part of the basic materials sector and chemicals industry. Shares are up 6.22% year-to-date as of the close of trading on Monday.

Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, performance materials, equipment, and services worldwide. The company operates through four segments: Merchant Gases, Tonnage Gases, Electronics and Performance Materials, and Equipment and Energy. The stock currently has a dividend yield of 2.4%. The company has a P/E ratio of 24.8. Currently there are 6 analysts that rate Air Products & Chemicals a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on APD - FREE

TheStreet Quant Ratings rates Air Products & Chemicals as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, good cash flow from operations, growth in earnings per share, solid stock price performance and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Air Products & Chemicals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

5 Stocks That Are Screaming Buys Right Now

5 Stocks That Are Screaming Buys Right Now

General Electric Booted From Dow, Replaced by Walgreens

General Electric Booted From Dow, Replaced by Walgreens

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

European Union Says Tariffs on U.S. Imports Will Kick In on June 22

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Stocks Rise, GE Dropped From the Dow, Starbucks, Oracle - 5 Things You Must Know

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge

Global Stocks Rebound But US-China Trade War Concerns Keep Investors on Edge